ATE328112T1 - Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon - Google Patents

Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon

Info

Publication number
ATE328112T1
ATE328112T1 AT03005186T AT03005186T ATE328112T1 AT E328112 T1 ATE328112 T1 AT E328112T1 AT 03005186 T AT03005186 T AT 03005186T AT 03005186 T AT03005186 T AT 03005186T AT E328112 T1 ATE328112 T1 AT E328112T1
Authority
AT
Austria
Prior art keywords
reagents
compositions
testing methods
anaplastic lymphoma
lymphoma kinase
Prior art date
Application number
AT03005186T
Other languages
English (en)
Inventor
Lorenzo A Pinna
Arianna Donella-Deana
Oriano Marin
Luca Mologni
Rosalind Gunby
Passerini Carlo Gambacorti
Leonardo Scapozza
Original Assignee
Ist Naz Stud Cura Dei Tumori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ist Naz Stud Cura Dei Tumori filed Critical Ist Naz Stud Cura Dei Tumori
Application granted granted Critical
Publication of ATE328112T1 publication Critical patent/ATE328112T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03005186T 2003-03-07 2003-03-07 Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon ATE328112T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03005186A EP1454992B1 (de) 2003-03-07 2003-03-07 Anaplastisches Lymphoma Kinase Testverfahren, Reagenzien und Kompositionen davon

Publications (1)

Publication Number Publication Date
ATE328112T1 true ATE328112T1 (de) 2006-06-15

Family

ID=32798804

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03005186T ATE328112T1 (de) 2003-03-07 2003-03-07 Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon

Country Status (14)

Country Link
US (1) US20070031907A1 (de)
EP (1) EP1454992B1 (de)
JP (1) JP2006519800A (de)
CN (1) CN100345978C (de)
AT (1) ATE328112T1 (de)
CA (1) CA2518094A1 (de)
CY (1) CY1106115T1 (de)
DE (1) DE60305634T2 (de)
DK (1) DK1454992T3 (de)
ES (1) ES2263862T3 (de)
IL (1) IL170669A0 (de)
PT (1) PT1454992E (de)
SI (1) SI1454992T1 (de)
WO (1) WO2004079326A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PT2450437T (pt) 2006-04-14 2017-08-25 Cell Signaling Technology Inc Defeitos de genes e cinase alk mutante em tumores sólidos humanos
EP2107054A1 (de) 2008-04-01 2009-10-07 Università Degli Studi Di Milano - Bicocca Antiproliferative Verbindungen und therapeutische Verwendungen dafür
EP2274288A2 (de) 2008-04-24 2011-01-19 Incyte Corporation Makrocyclische verbindungen und ihre verwendung als kinaseinhibitoren
EP2161271A1 (de) 2008-09-08 2010-03-10 Università Degli Studi Di Milano - Bicocca Alpha-Carbolin-Hemmer von NMP-ALK, RET und Bcr-Abl
WO2010085597A1 (en) 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
ES2575084T3 (es) * 2009-06-10 2016-06-24 Chugai Seiyaku Kabushiki Kaisha Compuesto tetracíclico
CN101955995B (zh) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 淋巴瘤相关的融合基因的诊断试剂盒
US20120101108A1 (en) * 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
CN103052386B (zh) 2010-08-20 2016-03-02 中外制药株式会社 含有四环化合物的组合物
EP2847353B1 (de) 2012-05-10 2022-01-19 The General Hospital Corporation Verfahren zur bestimmung einer nukleotidsequenz
MY170904A (en) 2012-09-25 2019-09-13 Chugai Pharmaceutical Co Ltd Ret inhibitor
JP2016509045A (ja) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト がんを治療し、薬剤耐性を防止する方法
EP3099820A4 (de) 2014-01-27 2018-01-03 The General Hospital Corporation Verfahren zur herstellung von nukleinsäuren zur sequenzierung
TWI831128B (zh) 2014-04-25 2024-02-01 日商中外製藥股份有限公司 以高用量含有4環性化合物的製劑
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 4環性化合物の新規結晶
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含4環性化合物的非晶質體之固體分散體及製劑
KR102584344B1 (ko) 2015-01-16 2023-09-27 추가이 세이야쿠 가부시키가이샤 병용 의약
US10704082B2 (en) 2016-09-15 2020-07-07 ArcherDX, Inc. Methods of nucleic acid sample preparation
WO2018053365A1 (en) 2016-09-15 2018-03-22 ArcherDX, Inc. Methods of nucleic acid sample preparation for analysis of cell-free dna
ES2940620T3 (es) 2016-11-02 2023-05-09 Archerdx Llc Métodos de preparación de muestras de ácido nucleico para la secuenciación del repertorio inmunitario
BR112020025499A2 (pt) 2018-06-29 2021-03-09 Chugai Seiyaku Kabushiki Kaisha Composição farmacêutica que compreende agente básico pouco solúvel
PL3848361T3 (pl) 2018-09-04 2025-07-07 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania związku tetracyklicznego

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05126833A (ja) * 1991-10-31 1993-05-21 Tosoh Corp チロシンキナ−ゼ活性の免疫化学的測定法及びそのキツト
WO1993021230A1 (en) * 1992-04-10 1993-10-28 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
US5344926A (en) * 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
GB9314271D0 (en) * 1993-07-09 1993-08-18 Inst Of Cancer The Research Cell growth factor receptors
US6025145A (en) * 1993-11-23 2000-02-15 Genentech, Inc. Kinase receptor activation assay
US6001621A (en) * 1993-11-23 1999-12-14 Genetech, Inc. Protein tyrosine kinases
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
US5759787A (en) * 1996-08-26 1998-06-02 Tularik Inc. Kinase assay
CA2288221A1 (en) * 1997-04-28 1998-11-05 Sugen, Inc. Diagnosis and treatment of phosphatase 0r kinase-related disorders
WO2001004125A1 (en) * 1999-07-13 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives

Also Published As

Publication number Publication date
EP1454992B1 (de) 2006-05-31
CN1756850A (zh) 2006-04-05
SI1454992T1 (sl) 2006-10-31
DE60305634D1 (de) 2006-07-06
US20070031907A1 (en) 2007-02-08
CN100345978C (zh) 2007-10-31
WO2004079326A2 (en) 2004-09-16
DE60305634T2 (de) 2006-09-21
IL170669A0 (en) 2011-08-01
EP1454992A1 (de) 2004-09-08
CA2518094A1 (en) 2004-09-16
JP2006519800A (ja) 2006-08-31
WO2004079326A3 (en) 2004-12-09
PT1454992E (pt) 2006-09-29
DK1454992T3 (da) 2006-10-02
HK1068154A1 (en) 2005-04-22
ES2263862T3 (es) 2006-12-16
CY1106115T1 (el) 2011-06-08

Similar Documents

Publication Publication Date Title
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
WO2005111212A3 (en) Biological bar code
EA200501563A1 (ru) Пролекарства ингибиторов киназы pi-3
WO2005012574A3 (en) Biological bar-code
DK1706424T3 (da) FC-region varianter
DE60007095T2 (de) Calanolide zur hemmung von btk
CY1110225T1 (el) Κυκλικοι αναστολεις πρωτεϊνικης τυροσινικης κινασης
ATE420879T1 (de) Indolizine als kinaseproteinhemmer
MXPA04006271A (es) Derivados de indolinona utiles como inhibidores de la proteina cinasa.
ATE554087T1 (de) Neue kinaseinhibitoren
NO20073368L (no) Amid-promedikament av gemcitabin, sammensetninger og anvendelse derav
DE602004019812D1 (de) Marker für neuromyelitis optica
DK1847611T3 (da) Rhamnose-inducerbart ekspressionssystem
WO2002047535A3 (en) High throughput assay to detect inhibitors of the map kinase pathway
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
ATE413884T1 (de) Beta-secretase-substrat und seine verwendung
WO2004050842A3 (en) Atm kinase compositions and methods
DE602005016800D1 (de) Hif-prolylhydroxylase-aktivitätstest
ATE494548T1 (de) Reinigung, charakterisierung und wiederherstellung einer ubiquitin-e3-ligase
DE602004032465D1 (de) Referenzstandard zur charakterisierung von rosuvastatin
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
WO2003031941A3 (en) Detection and characterization of pyschoactives using parallel multi-site assays in neuronal tissue
ATE504833T1 (de) Verfahren zur bestimmung des phänotyps von zellen
DE602006021548D1 (de) Probenlyse und beschichtung einer reaktionsoberfläche

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1454992

Country of ref document: EP

REN Ceased due to non-payment of the annual fee